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Abstract
Background: Although uric acid (UA) is regarded as a risk factor for cardiovascular disease, whether UA is an
independent risk factor contributing to coronary artery calcification in chronic kidney disease (CKD) is not well
known. We evaluated whether UA level is associated with coronary artery calcium (CAC) score in a predialysis CKD
cohort.
Methods: A total of 1,350 subjects who underwent coronary computed tomography as part of the KoreaN Cohort
Study for Outcome in Patients With Chronic Kidney Disease were analysed. We conducted a logistic regression
analysis to evaluate the association between UA and the presence of CAC.
Results: CAC was detected in 705 (52.2 %) patients, and the level of UA was significantly higher in CAC > 0 patients.
UA showed a positive relationship with CAC > 0 in age- and sex-adjusted logistic regression analysis (Odds ratio
(OR) 1.11, 95 % confidence interval (CI) 1.04–1.19, P = 0.003). However, UA showed no association with CAC > 0 in
multivariate analysis. Further analysis showed that UA showed a positive association with CAC > 0 only in estimated
glomerual filtration rate (eGFR) > 60 ml/min/1.73 m2 (OR 1.23, 95 % CI 1.02–1.49, P = 0.036) but not in eGFR 30–59
ml/min/1.73 m2 (OR 0.92, 95 % CI 0.78–1.08, P = 0.309) or < 30 ml/min/1.73 m2 (OR 0.92, 95 % CI 0.79–1.08, P =
0.426).
Conclusions: UA level was significantly associated with CAC in early CKD, but not in advanced CKD.
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Background
Cardiovascular disease (CVD) is the leading cause of
morbidity and mortality in patients with chronic kidney
disease (CKD), accounting for more than half of the
deaths [1]. Patients with CKD have traditional risk fac-
tors for CVD, such as hypertension, diabetes, dyslipid-
emia, and elderly. In addition, CKD-related risk factors
such as endothelial dysfunction, hyperphosphatemia,
vascular calcifications, and chronic inflammation play
important roles in the advancement of the disease [2].
Vascular calcification is a common complication in
CKD, resulting from altered mineral homeostasis and an
imbalance of calcification promoters and inhibitors [3,
4]. The extent and anatomic type of calcification are
well-known predictors of vascular mortality [5].
Coronary artery calcification is significantly associated
with the occurrence of major cardiovascular events. As
measured by multi-detector computed tomography, the
degree of calcification is one of the most widely accepted
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tools for detecting coronary atherosclerosis and estimat-
ing coronary risk assessment with high sensitivity and
specificity [6]. This tool is valid not only in asymptom-
atic adults [7, 8] but also in the CKD population [9].
Therefore, the coronary artery calcium (CAC) score is
now used to assess cardiovascular risk in patients with
CKD.
Uric acid (UA), the end product of purine catabolism,
has been in the spotlight for decades as a risk factor for
cardiovascular disease. Many epidemiologic studies have
revealed that hyperuricemia is associated with an in-
creased risk of coronary heart disease [10], heart failure
[11], and fatal arrhythmias [12]. UA showed a positive
association with CAC in health screening for the general
population [13–16] and elevated UA could predict the
development of coronary artery calcification progression
[17]. However, few studies have investigated the relation-
ship between UA and CAC in the CKD population.
Therefore, in this study, we sought to demonstrate
whether serum UA level is associated with CAC in the
predialysis CKD population.
Methods
Study design and population
This was a cross-sectional study designed to assess the
association between serum UA and CAC in patients
with CKD. The study population consisted of partici-
pants in the KoreaN Cohort Study for Outcome in Pa-
tients With Chronic Kidney Disease (KNOW-CKD), a
nationwide prospective cohort study, including CKD
stage 1 to 5 nondialysis patients, that was designed to
clarify the natural course and complication profiles of
CKD. Details of the KNOW-CKD study’s rationale and
design have been described previously [18] and the base-
line characteristics of the study population were previ-
ously published [19]. A total of 2,238 subjects were
initially screened. After excluding 126 participants who
had not performed coronary artery computed tomog-
raphy, 434 participants who had taken UA lowering
medication, and 328 participants with missing informa-
tion in any one of the variables included in the study,
1350 participants were analysed.
Data collection
Baseline demographics and laboratory data were re-
trieved from the electronic data management system
(PhactaX, Seoul, Republic of Korea) with assistance from
the Division of Data Management at Seoul National
University Medical Research Collaborating Center.
Socio-demographic characteristics, smoking history,
medication, and comorbidities were collected at the time
of enrollment. Anthropometric indexes including height,
weight, waist circumference, hip circumference, and
resting blood pressure (BP) were measured in the clinic.
Laboratory data were analysed at the hospital laboratory
of each participating centre. Serum samples were col-
lected and sent to the central laboratory (Lab Genomics,
Seoul, Republic of Korea) to measure creatinine levels.
The estimated glomerular filtration rate (eGFR) was cal-
culated through the CKD-EPI equation [20].
CAC score was evaluated at each research institution
by an electron-beam computed tomography (CT) scan-
ner or a multi-detector CT. Specifically, SOMATOM
Definition Flash (Siemens Healthineers), SOMATOM
Force (Siemens Healthineers), Revolution CT (GE
healthcare), Discovery CT750 HD (GE Healthcare), Bril-
liance iCT 256 slice (Philips Medical Systems), Brilliance
64 CT scanner (Philips Medical Systems), IQon Spectral
CT (Philips Medical Systems) were used. The quantita-
tive CAC score was assessed using the Agatston score
[21]; If a lesion with a density of 130 Hounsfield unit
(less than HU) and a width of 1 mm2 or more is in the
coronary artery position, it is determined as positive. In
each lesion, 1 point for 130 to 199 HU, 2 for 200 to 299
HU Points, 3 points for 300 ~ 399 HU, 4 points for 400
or more, were measured as the sum of these values.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation, and categorical variables were expressed as
numbers and proportions. The comparisons were made
using the independent t-test or analysis of variance for
continuous variables and the chi-squared test for cat-
egorical variables. A P-value < 0.05 was considered statis-
tically significant. The adjusted odds ratios of CAC > 0
associated with risk factors were estimated using logistic
regression analysis. Only covariates that were significant
(p < 0.05) were retained in the multivariable analysis.
The independent association between UA and CAC was
also evaluated using restricted cubic splines. To visualise
the association of UA and CAC, selected knots automat-
ically, cubic splines were drawn by the “gam,” “mgcv”
packages in R. Statistical analysis was performed using R
software (version 3.2.2).
Ethics statement
This study was conducted in accordance with the Dec-
laration of Helsinki. The study protocol was approved by
the institutional review board at each participating hos-
pital, including Seoul National University Hospital
(1104-089-359), Seoul National University Bundang
Hospital (B-1106/129-008), Yonsei University Severance
Hospital (4-2011-0163), Kangbuk Samsung Medical
Center (2011-01-076), Seoul St. Mary’s Hospital
(KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji Gen-
eral Hospital (201105-01), Chonnam National University
Hospital (CNUH-2011-092), and Pusan Paik Hospital
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(11–091). All participants provided written informed
consent.
Results
Clinical characteristics of participants with CAC
The mean age was 53.5 ± 11.9 years, and 758 (56.2 %)
were men. Seventy (5.2 %) had a history of coronary
artery disease, 499 (37.0 %) had diabetes mellitus, and
1286 (95.3 %) had hypertension. The mean eGFR was
56.7 ± 32.4 ml/min/1.73 m2, and the serum UA level
was 7.0 ± 1.9 mg/dL. Of these, 645 (47.8 %) belonged
to CACS 0 and 705 (52.2 %) belonged to CACS > 0.
Table 1 shows the clinical characteristics of CAC 0
and CAC > 0. Compared to those with CAC 0, partici-
pants with CAC > 0 were older and had a higher pro-
portion of males. Comorbidities, such as coronary
artery disease, diabetes mellitus, and hypertension,
were higher in CAC > 0, and the proportion of
current smokers and lipid-lowering medications was
also higher. The UA, phosphate, PTH, and 24-hour
urine protein levels were significantly higher in partic-
ipants with CAC > 0. In contrast, the levels of eGFR,
calcium, LDL-cholesterol, and HDL-cholesterol were
significantly lower in CAC > 0.
We further divided as CAC 0, > 0–100, > 100–400, >
400. The participants with high CAC score were older
and had higher proportion of male, coronary artery dis-
ease, diabetes mellitus and hypertension. The level of
eGFR, calcium, LDL cholesterol, and HDL cholesterol
were lower, whereas uric acid, phosphate, PTH, and
24 h urine protein were higher according to higher CAC
level (Supplementary Table 1).
Association factors with CAC
Table 2 lists several factors associated with CAC > 0.
The age- and sex-adjusted logistic regression analysis re-
vealed UA (Odds ratio (OR) 1.11, 95 % confidence inter-
val (CI) 1.04–1.19, P = 0.003) was significantly associated
with having CAC > 0. However, on multivariate logistic
regression analysis, adjusted for age, sex, coronary artery
disease, diabetes mellitus, use of lipid-lowering agents,
mean BP, waist-hip ratio, eGFR, calcium, phosphate,
LDL-cholesterol, HDL-cholesterol, PTH, and 24-hour
urine protein, UA showed no association with CAC > 0
(OR 1.00, 95 % CI 0.91–1.09, P = 0.953). History of cor-
onary artery disease, history of diabetes mellitus, use of
lipid-lowering agents, mean BP, and phosphate levels
were positively associated with CAC in multivariate
analysis.
We further divided the participants by eGFR ≥ 60, 30–
59, and < 30 ml/min/1.73 m2. UA level showed a positive
association with CAC > 0 (OR 1.23, 95 % CI 1.02–1.49,
P = 0.036) only in estimated GFR > 60 ml/min/1.73 m2
(Table 3). UA had no association with CACS in eGFR
30–59 ml/min/1.73 m2 (OR 0.92, 95 % CI 0.78–1.08, P =
0.309) or 30 ml/min/1.73 m2 (OR 0.92, 95 % CI 0.79–
Table 1 Clinical characteristics of participants
Total (n = 1350) CAC 0 (n = 645) CAC > 0 (n = 705) P value
Age, year 53.5 ± 11.9 47.6 ± 11.3 58.8 ± 9.8 < 0.0001
Sex, male (%) 758 (56.2) 277 (43.0) 481 (68.2) < 0.0001
Coronary artery disease (%) 70 (5.2) 2 (0.3) 68 (9.7) < 0.0001
Diabetes mellitus (%) 499 (37.0) 97 (15.0) 402 (57.0) < 0.0001
Hypertension (%) 1286 (95.3) 593 (91.9) 693 (98.3) < 0.0001
current smoker (%) 217 (16.1) 88 (13.6) 129 (18.3) 0.020
Use of lipid-lowering drugs (%) 727 (53.9) 279 (43.3) 448 (63.6) < 0.0001
Mean blood pressure, mmHg 94.0 ± 11.6 93.1 ± 11.3 94.8 ± 11.9 0.005
Waist hip ratio (%) 89.8 ± 7.2 87.6 ± 7.8 91.8 ± 5.8 < 0.0001
Creatinine, mg/dL 1.72 ± 1.12 1.44 ± 0.93 1.98 ± 1.21 < 0.0001
eGFR, ml/min/1.73m2 56.7 ± 32.4 67.3 ± 33.9 47.1 ± 27.5 < 0.0001
Uric acid, mg/dL 7.0 ± 1.9 6.7 ± 2.0 7.3 ± 1.9 < 0.0001
Calcium, mg/dL 9.1 ± 0.5 9.2 ± 0.49 9.1 ± 0.6 < 0.0001
Phosphate, mg/dL 3.7 ± 0.7 3.6 ± 0.6 3.8 ± 0.7 < 0.0001
LDL cholesterol, mmol/L 98.4 ± 31.9 102.6 ± 29.9 94.5 ± 33.1 < 0.0001
HDL cholesterol, mmol/L 50.0 ± 15.8 53.6 ± 15.5 46.8 ± 15.4 < 0.0001
Ln PTH, pg/mL 3.95 ± 0.74 3.85 ± 0.70 4.05 ± 0.77 < 0.0001
Ln 24 h urine protein, mg 6.1 ± 1.8 5.7 ± 1.9 6.5 ± 1.6 < 0.0001
eGFR estimated glomerular filtration rate, LDL low density lipoprotein, HDL high density lipoprotein, PTH parathyroid hormone
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1.08, P = 0.426). Restricted cubic splines of UA on the
CAC > 0, stratified by eGFR, showed that CAC increased
steadily with higher UA levels only in estimated GFR >
60 ml/min/1.73 m2 (Fig. 1).
Discussion
In the present study, we showed that over half of the
CKD population had CAC. The patients with CAC > 0
had higher UA levels than those with CAC 0, and UA
showed a positive relationship with CAC > 0 in age- and
sex-adjusted logistic regression analysis. However, UA
showed an association with CAC > 0 in multivariate-
adjusted logistic regression analysis only in the early
stage of CKD, and this association disappeared in ad-
vanced CKD.
UA, formerly considered a significant antioxidant in
humans, has been regarded as a risk factor for cardio-
vascular disease in the past two decades. Previous
studies have shown that elevated UA levels could pre-
dict the severity and morphology of coronary athero-
sclerosis [16] and elevated UA is associated with
greater lipid content of coronary plaque in patients
with acute coronary syndrome [22]. In line with this,
hyperuricemia showed a positive association with
CAC in the general population in previous studies
[13, 15]. Several experimental studies have demon-
strated the mechanism of UA in atherosclerosis. In
endothelial cells, UA decreases nitric oxide bioavail-
ability and inhibits cell migration and proliferation
[23, 24]. UA significantly increased the production of
reactive oxygen species, facilitated the activation of
the renin-angiotensin system [25], and induced endo-
thelial dysfunction. In addition, UA has been shown
to have pro-inflammatory activity. UA triggers the
expression of pro-inflammatory cytokines such as
C-reactive protein [26, 27], contributing to
atherosclerosis.
However, UA failed to show an association with CAC
in patients with CKD, not only in this study population
but also in another CKD cohort [28]. The authors be-
lieve that this is due to the complex process of vascular
calcification in CKD. Vascular calcification can occur in
two areas of the vessel wall: the intima and the media.
Intima calcification is associated with atherosclerosis,
whereas calcification in the media is associated with
Table 2 Multivariate-adjusted odds ratios of CAC >0 associated with several risk factors
age-, sex- adjusted OR Multivariate-Adjusted OR
OR (95% CI) p-value OR (95% CI) p-value
Current smoker 1.29 (0.90, 1.85) 0.169 - -
Coronary artery disease 23.0 (5.3, 100.6) <.0001 10.44 (2.45, 44.48) 0.002
Hypertension 2.04 (0.98, 4.24) 0.057 - -
Diabetes mellitus 5.12 (3.83, 6.86) <.0001 3.53 (2.56, 4.87) <.0001
Use of lipid-lowering drugs 1.66 (1.29, 2.14) <.0001 1.37 (1.02, 1.84) 0.039
Mean blood pressure 1.02 (1.01, 1.03) <.0001 1.02 (1.01. 1.03) 0.006
Waist hip ratio 1.05 (1.03, 1.07) <.0001 1.02 (1.00, 1.05) 0.075
eGFR 0.99 (0.98, 0.99) <.0001 1.00(0.99, 1.01) 0.591
Uric acid 1.11 (1.04, 1.19) 0.003 1.00 (0.91, 1.09) 0.953
Calcium 0.64 (0.50, 0.81) <.0001 0.83 (0.61, 1.11) 0.206
Phosphate 1.82 (1.47, 2.24) <.0001 1.31 (1.02, 1.68) 0.032
LDL cholesterol 1.00 (0.99, 1.00) 0.038 1.00 (1.00, 1.00) 0.775
HDL cholesterol 0.98 (0.97, 0.99) <.0001 0.99 (0.98, 1.00) 0.171
Ln PTH 1.49 (1.25, 1.78) <.0001 1.03 (0.81. 1.32) 0.793
Ln 24hour urine protein 1.24 (1.14, 1.34) <.0001 0.99 (0.90, 1.10) 0.909
eGFR estimated glomerular filtration rate, LDL low density lipoprotein, HDL high density lipoprotein, PTH parathyroid hormone
Table 3 Multivariate-adjusted odds ratios (95 % Confidence
Intervals) for CAC > 0 associated with serum uric acid according
to CKD stages
n OR (95% CI) p-value
eGFR≥ 60ml/min/1.73 m2 541
Uric acid 1.23 (1.02, 1.49) 0.036
eGFR 30-59ml/min/1.73 m2 475
Uric acid 0.92 (0.78, 1.08) 0.309
eGFR < 30 ml/min/1.73 m2 334
Uric acid 0.92 (0.79, 1.08) 0.426
CKD chronic kidney disease
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advanced age, diabetes, and CKD [29]. Abnormal cal-
cium and phosphate levels and parathyroid hormone
levels in kidney disease contribute to the phenotype
switch of vascular smooth muscle cells to osteoblast-
like cells and local inflammation, contributing to vascu-
lar calcification [4].
Unlike UA, phosphate showed a positive association
with CAC throughout the whole stage of CKD in this
study. Phosphate is an integral component of hydroxy-
apatite, the calcium mineral seen in bone and vascular
calcification. It is also a part of the signalling cascade
that triggers vascular calcification [29]. Calcification of
the coronary arteries is independently associated with
hyperphosphatemia in patients with end-stage renal dis-
ease, and elevated phosphate levels, even those in the
high-normal range, are correlated with a higher risk of
myocardial infarction and mortality in patients with
CKD [30].
This study has some limitations. This is a cross-
sectional study; therefore, we could not identify a longi-
tudinal relationship between UA and CAC. Moreover,
this study could not confirm that UA is associated with
cardiovascular events in patients with CKD. CAC is a
complex process; therefore, there could be confounders
that we could not consider. However, this study is the
first, to the best of our knowledge, to elucidate that UA
showed a different relationship with CAC according to
CKD stages.
Conclusions
The UA level was significantly associated with CAC in
early CKD but not in advanced CKD. Longitudinal stud-
ies are required to confirm the association between UA
and CAC and the effect of UA lowering therapy for
CAC in patients with CKD.
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